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CASE REPoRT
The prognosis for non-small cell lung cancer (NSCLC) is generally poor, but relapse-free survival exceeding 5 
years is often considered proof of cure. This report com-
pares prognostic factors influencing long-term overall sur-
vival and progression-free survival in NSCLC with a case of 
ultra-late relapse 10 years after initial treatment.
METHODS
Literature search using PubMed database and Co- 
chrane Library with no limitation concerning time period 
was updated until September 12. only English  literature 
was searched and the following keywords were used: 
NSCLC, non-small cell lung cancer, late relapse, and late 
recurrence.
CASE REPORT
A 60-year-old man with smoking cessation 10 years 
previously had left lower lobe lobectomy in october 2000. 
Histologic examination revealed highly differentiated 
bronchioalveolar carcinoma without vascular or pleural 
invasion and with spread to 2 intrapulmonary N1 lymph 
nodes out of 10 resected. Negative for EGFR mutation. CT 
scan was without signs of metastasis or mediastinal gland 
involvement, and mediastinoscopy was negative.
The operation was micro- and macroscopic com-
plete, and the surgical-pathological TNM classification 
was T2aN1M0 (stage IIA). No adjuvant chemotherapy was 
applied as this was not a standard treatment at that time. 
The patient developed vertigo and headache in July 2010, 
and cerebral magnetic resonance imaging scan revealed 
a cerebellar metastasis which was incompletely removed 
by neurosurgery. Whole brain irradiation was given. 
Histopathological examination with immunohistochemis-
try revealed the metastasis being similar to the bronchio-
alveolar carcinoma treated 10 years earlier. Examination 
with positron emission tomography-computed tomography 
fused imaging and cerebral magnetic resonance imaging 
scan showed no other relapse sites or sign of other primary 
tumor. The patient died in January 2011 due to intracranial 
progression.
DISCUSSION
The literature search revealed that the risk of recur-
rence 5 years after initial complete surgery varies from 
3.8 to 15.0% (Table 1). only one published study has been 
found with data on ultra-late relapse 10 years or more after 
treatment.1 These numbers should be interpreted care-
fully because there is no consensus between definition of 
late relapse and newly developed malignant disease in the 
literature.
Maeda et al.2 reported the most important prognos-
tic factors for development of recurrence to be lymph node 
involvement, intratumoral vascular invasion, smoking hab-
its, carcinoembryonal antigen, histologic condition, pleural 
invasion, and pathologic stage.
Similarly, Wang et al.3 observed correlation between 
resectable lymph nodes and 5-year survival, while Martini 
et al.1 found age, sex, histologic condition, or stage, 
 including N-status, to not influence 5-year survival.
Likewise, okada et al.4 reported that for patients alive 
5 years after initial treatment, neither age, nodal status, sex, 
or histologic condition affected subsequent survival. In 
contrast, these factors were found to have prognostic value 
before 5 years. Also, Pasini et al.5 found no correlation 
between vascular or lymphatic invasion and 5-year survival 
or 5-year progression-free survival.
These findings support that lung cancer is very het-
erogeneous in outcome and more individual, targeted treat-
ment is obviously needed to improve long-term survival. 
The case also supports this, as the patient developed a cer-
ebellar metastasis 10 years after initial treatment despite 
positive prognostic factors. This may suggest that other 
factors may be of influence, e.g., presence of oncogenic 
driver mutations or other biological factors.
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TABLE 1. Frequency and Sites of Late Relapse in NSCLC
 Maeda et al.  
(2010)
Wang et al.  
(2010)
Okada et al.  
(2003)
Pasini et al.  
(2002)
Martini et al.  
(1999)
Total population, n 1358 846 848 241 686
Recurrence free .5 yr, n (%) 819 (60.3) 56 (6.6)a  421 (49.6)a 150 (62) 686 (100)
Late recurrence after 5 yr, n (%)   87 (10.6) b b 22 (15) 26 (3.8)c
Initial stages IA–IIIB IIIA–IV IA–IIIB I (T1–2N0M0) IA–IIIA
Histology      
 Adenocarcinoma 585 (43.0) b 245 (58.2)   99 (41.0) 412 (60.0)
 Squamous cell 179 (13.2)  160 (38.0) 130 (54.5) 244 (36.0)
 Large cell 33 (2.4)    8 (1.9) 10 (4.0) 29 (4.0)
 others 22 (1.6)    8 (2.0) 2 (0.8) 1 (0.1)
Treatment Surgery Surgery Surgery Surgery Surgery
 RT    
 Chemotherapy    
Site of late recurrence after 5 yr, n (%)      
 Locoregional   38 (43.7) b b d     6 (23.1)
 Contralateral lung —        3 (11.5)
 Brain   4 (4.6)        9 (34.6)
 Bone   4 (4.6)      2 (7.7)
  one site   22 (25.3)        4 (15.4)
 other   19 (21.8)      2 (7.7)
a Study does not elaborate whether the patients are disease free or not but only if they are alive.
b Is not calculated or specified in the study.
c Study composes of population who have survived the first 5 yr. Therefore, this number represents 10 yr after initial treatment. Study has distinguished local recurrence from 
secondary malignant tumors. Hence, this number is lower than that of Pasini et al.
d 14/20 of the late recurrences were inside the thorax.
